During the last decade, cell therapy has revolutionized the way cancer treatment is delivered and changed the focus of patient care from delayed disease progression to complete remission.
While Western scientists have been leading players in cell therapy research, Asia is increasingly playing a significant role in translating cell therapy-based regimens into solutions for patients, with China now leading the world in the number of ongoing investigative clinical trials. Japanese academic researchers are also working towards advancing this science, particularly around iPSC-derived allogenic approaches.
At Johnson & Johnson, we are striving to bring the latest advances to patients with potentially transformative health outcomes by collaborating with innovators across the life science ecosystem, including academia and biotech.
Join us on the 19 June 2020 as we convene global and regional experts to provide an insightful overview of cell therapy in oncology including IPSC-based approaches.
